JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

Kodu・Aktsiate loetelu・Vaxart Inc

Vaxart Inc

Suletud

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Põhinäitajad
By Trading Economics
Sissetulek	63M 55M
Müük	32M 104M
P/E Sektori keskmine	10.856 60.328
Aktsiakasum	0.24
Kasumimarginaal	52.807
Töötajad	65
EBITDA	63M 58M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-8.2M 184M
Eelmine avamishind	0
Eelmine sulgemishind	0

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.4007 / 0.4252 Toetus ja vastupanu

Vaxart Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. apr 2026, 00:00 UTC

Uudisväärsed sündmused

Australian Flash PMI Bounce in April Conceals Deeper Worries

22. apr 2026, 23:33 UTC

Tulu

SK Hynix Posts Record Quarterly Results Amid AI Boom

22. apr 2026, 22:40 UTC

Tulu

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

22. apr 2026, 22:10 UTC

Omandamised, ülevõtmised, äriostud

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

22. apr 2026, 21:11 UTC

Tulu

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

22. apr 2026, 21:01 UTC

Tulu

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

22. apr 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

22. apr 2026, 23:46 UTC

Market Talk

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

22. apr 2026, 23:34 UTC

Market Talk

Uudisväärsed sündmused

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

22. apr 2026, 23:16 UTC

Tulu

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

22. apr 2026, 23:15 UTC

Tulu

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

22. apr 2026, 22:54 UTC

Tulu

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

22. apr 2026, 22:54 UTC

Tulu

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

22. apr 2026, 22:52 UTC

Tulu

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

22. apr 2026, 22:51 UTC

Tulu

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

22. apr 2026, 22:31 UTC

Tulu

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

22. apr 2026, 22:31 UTC

Tulu

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

22. apr 2026, 22:30 UTC

Tulu

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

22. apr 2026, 22:30 UTC

Tulu

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

22. apr 2026, 22:29 UTC

Tulu

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

22. apr 2026, 22:28 UTC

Tulu

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

22. apr 2026, 22:28 UTC

Tulu

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

22. apr 2026, 22:27 UTC

Tulu

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

22. apr 2026, 22:06 UTC

Market Talk

Tulu

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

22. apr 2026, 21:55 UTC

Omandamised, ülevõtmised, äriostud

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

22. apr 2026, 21:47 UTC

Tulu

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22. apr 2026, 21:37 UTC

Tulu

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

22. apr 2026, 21:34 UTC

Tulu

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

22. apr 2026, 21:29 UTC

Tulu

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22. apr 2026, 21:20 UTC

Market Talk

Tulu

Tesla Expands Manufacturing to Chips -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Vaxart Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Vaxart Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.4007 / 0.4252Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.